Medivo Acquires Top-Rated Mobile App, OnTrack Diabetes

Medivo Acquires Top-Rated Mobile App, OnTrack Diabetes

More Than Half a Million Patients Have Already Downloaded the Mobile App to Help Manage Their Diabetes

NEW YORK--(BUSINESS WIRE)-- Medivo Inc. today announced that it has acquired OnTrack Diabetes as part of the company's continued focus to help physicians with patient treatment and care. This top-rated app will be instrumental in helping physicians coordinate patient care and can be recommended to monitor key clinical changes between office visits.

The free, highly rated app helps diabetics manage their diabetes by tracking various items such as blood glucose, food intake, medication, blood pressure (BP), pulse, exercise and weight. The app also produces charts, graphs and reports for optimal care coordination. The OnTrack app has been downloaded by more than a half million users and it has an average rating of 4.5 stars (based on 4,000 user reviews) in Google Play. It is available for Android devices.

"We are extremely excited about adding the powerful OnTrack Diabetes app as a resource for patients to monitor their symptoms and to create reports that can be shared with their physician," said Sundeep Bhan, Chief Executive Officer and a Co-Founder of Medivo. "This acquisition also fits with our growth strategy, enhances our consumer app portfolio and furthers our plans to develop new patient and physician engagement services."

OnTrack Diabetes was developed by GExperts Inc. of Newmarket, Ontario. The app's features include an easy-to-use interface that simplifies adding new entries, a variety of useful graphs and reports, a detailed log book that is easily shared with a physician and a functional reminder program that can be set to alert users to glucose test two hours after eating.

The OnTrack Diabetes app adds to Medivo's mobile app portfolio, which includes apps for the management of inflammatory bowel disease (IBD) / Crohn's and ulcerative colitis; hereditary angioedema (HAE), and chronic myelogenous leukemia (CML). Medivo's apps allow patients to easily track symptoms, view recent lab results and communicate with fellow patients in real-time.

Diabetes is one of the most prevalent chronic conditions in the United States. According to the Centers for Disease Control, there are 25.8 million people living with diabetes, or 8.3% of the U.S. population, and the incidence is rising.

Earlier this year, Medivo raised a $15 million Series B financing round that it is using to expand its analytics capabilities and innovative health data platform. The Medivo HIPAA-compliant platform also includes resources to help physicians and patients in condition-specific areas such as diabetes, dyslipidemia, hepatitis C, gout and low testosterone.

About Medivo

Medivo is the emerging, cloud-based Lab Data Exchange that provides doctors timely clinical lab information on their patients. Its unique access to clinical data and advanced analytics simplifies and improves health interactions between physicians and patients. Medivo makes it easy to access lab tests and to measure and track health information. All services—including mobile tools and simple explanations of lab results—are free for physicians and consumers. New York City-based Medivo is venture-backed by investors, including Merck Global Health Innovation Fund (GHIF), Safeguard Scientifics, Inc. (NYS: SFE) , and MentorTech Ventures. For more information, visit our website at or download our free apps for iPhone and Android.

Medivo Inc.
Mark Tosh
Director of Corporate Communications

KEYWORDS: United States North America New York


The article Medivo Acquires Top-Rated Mobile App, OnTrack Diabetes originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.